Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ensysce Biosciences Inc
ENSC | US
0.26
USD-0.02
-6.57%
ENSC | US
About Ensysce Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
0.26
Open
0.28
High
0.28
Low
0.26
Ensysce Biosciences Inc. a clinical-stage pharmaceutical company engages in developing various prescription drugs for severe pain relief in opioid misuse abuse and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform an over-dose protection opioid prodrug technology. The company is developing PF614 a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases such as cystic fibrosis. It is also developing PF614 an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla California.
View LessENSC | US
Risk
107.2
Sharpe
-0.82
Luna's Score
37/100
Recommendation
Sell
Luna says (ENSC | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
66.6%1 month
107.2%3 months
123.9%6 months
151.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.38
Debt to equity
0.25
Debt to assets
0.16
Ent. to EBITDA
-0.50
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-24.22M
MarketCap
3.63M
MarketCap(USD)
3.63M
Div. yield
-
Op. margin
-1.08K
Erngs. growth
-
Rev. growth
-62.90
Ret. on equity
-427.89
Short ratio
0.54
Short perc.
2.09
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.06
Range1M
0.20
Range3M
0.52
Volumes: Market Activity
Rel. volume
0.13
Price X volume
177.86K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.50 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.38 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 123.94 | - | Riskier |
| Debt to Equity | 0.25 | -1.23 | Expensive |
| Debt to Assets | 0.16 | 0.25 | Cheaper |
| Market Cap | 3.63M | - | Emerging |
